Skye Bioscience IncNASDAQ:SKYE
- LAST PRICE4.1700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.0500/ 2
- Ask / Lots5.0000/ 1
- Open / Previous Close--- / 4.1700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SKYE |
|---|---|---|
| 09:32 ET | 1142 | 4.24 |
| 09:33 ET | 420 | 4.365 |
| 09:35 ET | 500 | 4.365 |
| 09:37 ET | 382 | 4.315 |
| 09:42 ET | 200 | 4.315 |
| 09:48 ET | 100 | 4.315 |
| 09:55 ET | 750 | 4.38 |
| 10:04 ET | 300 | 4.315 |
| 10:06 ET | 100 | 4.325 |
| 10:09 ET | 100 | 4.32 |
| 10:13 ET | 100 | 4.33 |
| 10:20 ET | 200 | 4.33 |
| 10:27 ET | 750 | 4.3 |
| 10:38 ET | 100 | 4.285 |
| 10:47 ET | 400 | 4.31 |
| 10:54 ET | 10444 | 4.265 |
| 11:00 ET | 200 | 4.28 |
| 11:02 ET | 100 | 4.3 |
| 11:03 ET | 100 | 4.25 |
| 11:12 ET | 100 | 4.285 |
| 11:21 ET | 2595 | 4.325 |
| 11:23 ET | 300 | 4.325 |
| 11:27 ET | 100 | 4.33 |
| 11:32 ET | 495 | 4.37 |
| 11:34 ET | 2048 | 4.4 |
| 11:38 ET | 200 | 4.4 |
| 11:43 ET | 1427 | 4.34 |
| 11:59 ET | 100 | 4.36 |
| 12:08 ET | 200 | 4.35 |
| 12:12 ET | 100 | 4.34 |
| 12:21 ET | 100 | 4.31 |
| 12:28 ET | 200 | 4.31 |
| 12:30 ET | 2000 | 4.32 |
| 12:32 ET | 3100 | 4.325 |
| 12:33 ET | 892 | 4.35 |
| 12:35 ET | 1617 | 4.34 |
| 12:37 ET | 1999 | 4.3001 |
| 12:39 ET | 2382 | 4.3037 |
| 12:46 ET | 1200 | 4.2936 |
| 12:48 ET | 600 | 4.29 |
| 12:50 ET | 902 | 4.27 |
| 12:51 ET | 1085 | 4.2314 |
| 12:55 ET | 2837 | 4.24 |
| 01:00 ET | 700 | 4.2537 |
| 01:08 ET | 100 | 4.21 |
| 01:15 ET | 250 | 4.2478 |
| 01:18 ET | 1100 | 4.28 |
| 01:20 ET | 100 | 4.29 |
| 01:22 ET | 100 | 4.32 |
| 01:33 ET | 100 | 4.29 |
| 01:54 ET | 100 | 4.29 |
| 01:58 ET | 600 | 4.29 |
| 02:00 ET | 200 | 4.29 |
| 02:02 ET | 6085 | 4.31 |
| 02:03 ET | 300 | 4.335 |
| 02:05 ET | 100 | 4.335 |
| 02:07 ET | 100 | 4.335 |
| 02:09 ET | 320 | 4.3 |
| 02:12 ET | 1100 | 4.255 |
| 02:21 ET | 800 | 4.2697 |
| 02:36 ET | 200 | 4.29 |
| 02:45 ET | 100 | 4.28 |
| 02:48 ET | 100 | 4.285 |
| 02:52 ET | 100 | 4.285 |
| 02:54 ET | 808 | 4.26 |
| 02:57 ET | 100 | 4.25 |
| 03:03 ET | 100 | 4.255 |
| 03:06 ET | 200 | 4.2563 |
| 03:12 ET | 3100 | 4.29 |
| 03:15 ET | 100 | 4.3152 |
| 03:17 ET | 100 | 4.32 |
| 03:19 ET | 445 | 4.32 |
| 03:21 ET | 1645 | 4.27 |
| 03:24 ET | 100 | 4.275 |
| 03:30 ET | 100 | 4.29 |
| 03:39 ET | 100 | 4.28 |
| 03:44 ET | 1345 | 4.25 |
| 03:46 ET | 100 | 4.245 |
| 03:50 ET | 201 | 4.24 |
| 03:53 ET | 120 | 4.23 |
| 03:55 ET | 200 | 4.255 |
| 03:57 ET | 9018 | 4.2 |
| 04:00 ET | 13312 | 4.17 |
Nov 18, 2024
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences, from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones
7:00AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 14, 2024
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor, from 7:01AM ET on Thursday Nov 14, 2024 by Dow Jones
7:01AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Press Release: Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow JonesSkye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Skye Bioscience Inc | 126.5M | -5.0x | --- |
Pyxis Oncology Inc | 124.9M | -2.0x | --- |
InflaRx NV | 121.3M | -2.0x | --- |
Vigil Neuroscience Inc | 122.6M | -1.4x | --- |
Cardiff Oncology Inc | 127.8M | -2.6x | --- |
Ventyx Biosciences Inc | 122.3M | -0.7x | --- |
Company Information
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.
Contact Information
- Headquarters
- 11250 EL CAMINO REAL, SUITE 100SAN DIEGO, CA, United States 92130
- Phone
- 858-410-0266
- Fax
- 775-782-2611
Executives
- Independent Chairman of the Board
- Paul Grayson
- Chief Executive Officer, Director
- Punit Dhillon
- Chief Financial Officer
- Kaitlyn Arsenault
- Chief Medical Officer
- Puneet Arora
- Director
- Annalisa Jenkins
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $126.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.74 |
EPS | $-0.84 |
Book Value | $-0.17 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
